As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: March 13, 2014
by Medical XPress:
When initiated soon after menopause, hormone therapy with estradiol prevented degeneration in key brain regions of women who were at heightened dementia risk, according to a new study led by Stanford University School of Medicine researchers.
The investigators also found that another type of hormone therapy, marketed under the brand name Premarin, was far less protective. Premarin is a mixture of 30-plus substances derived from the urine of pregnant mares. Estradiol—the dominant sex-steroid hormone in woman—accounts for about 17 percent of Premarin’s total content. Other Premarin components exert various endocrinological effects on different tissues.
The randomized study sought to understand the effects of continuing versus stopping hormone therapy on cerebral metabolism. It will be published March 12 in PLOS ONE. The findings indicate that hormone therapy’s neurological effect on woemn at risk for dementia depends critically on when they begin therapy and on whether they use estradiol or Premarin, said lead author Natalie Rasgon, MD, PhD, professor of psychiatry and behavioral sciences and director of the Stanford Center for Neuroscience in Women’s Health.
The researchers observed brain regions in and around the hippocampus that are associated with memory and executive function. These regions are among the earliest to show deterioration in metabolic activity in many forms of dementia, ranging from mild cognitive impairment to Alzheimer’s disease.
When women who had started an estradiol regimen within a year of menopause stayed on the regimen, metabolic activity in a number of these brain regions was preserved. But it declined significantly among those who stopped using the hormone.
Staying on Premarin, however, actually appeared to accelerate some of these brain regions’ metabolic decline. If another hormone, progestin (essentially, synthetic progesterone), was taken along with either estradiol or Premarin, it obliterated estradiol’s neurological benefit and steepened the decline seen with Premarin.
The study, while too small to give meaningful results for direct tests of cognition, was large enough to achieve a high level of statistical significance for its imaging results.
Dr. Redd, a 76-year-old practicing physician, sought help for memory loss at an Alzheimer’s disease research center. After being diagnosed with Alzheimer’s, she became distressed when she was instructed...
The Alzheimer’s Association estimated the direct cost to American society of Alzheimer’s and other dementias to be $259 billion in 2017. Because of the increasing number of older individuals being diagnosed, there is an ever-increasing need for ways to treat and lower risk of dementia. A...
A new brain imaging study reveals structural brain changes in patients with sleep apnea as well as distinct differences between males and females with the condition. Obstructive sleep apnea, a disorder which involves disruption of...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.